Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference-fashion enews-Introducing international digital media and international bloggers copyrighted fashion brand new media

Newest

Intelligent Manufacturing in China Sets a New Benchmark for Design: GUTX Probiotic Dual-Compartment Fresh Probiotics Wins the 2025 French Design Awards
Safeguarding Livelihoods Amidst Geopolitical Tensions: CYCJET Safeguards Middle Eastern Supply Chains with Stable and Reliable Identification Technology
Functional Cure of Type 1 Diabetes - 30 Patients Discontinued Insulin: A Chinese Integrative Medicine Team Delivers a World-Class Clinical Innovation
International Anti-Fraud Cooperation Adds a New Initiative: International Anti-Fraud Alliance Releases Global Member Anti-Fraud Declaration Video

Links

Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

2025-01-03 IDOPRESS

SEONGNAM,South Korea and BOSTON,Dec. 30,2024 -- Bridge Biotherapeutics (KQ288330),a clinical-stage biotech company based inSouth Koreadeveloping novel drugs for fibrosis and cancer,today announced thatJames Jungkue Lee,Founder and CEO of Bridge Biotherapeutics,will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday,January 16,2025.

Location: Georgian Room (Mezzanine Level) at The Westin St. Francis

Date: Thursday,2025

Time: 9:45-10:25 a.m. PST

During the conference,BridgeBiotherapeutics will also meet with potential partners and investors as the Company is looking for Business Development opportunities for further development of BBT-877,a novel drug candidate for idiopathic pulmonary fibrosis (IPF). Top-line results from the Phase 2 study of BBT-877 are expected in April 2025.

To arrange a meeting with the Bridge Biotherapeutics team,send a meeting request here.

About Bridge Biotherapeutics,Inc.

Bridge Biotherapeutics Inc.,based in the Republic of Korea and the U.S.,is a publicly traded,clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics,focusing on therapeutic areas with high unmet needs,including fibrotic diseases and cancers. The company is developing BBT-877,a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF),and BBT-207,a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at https://www.bridgebiorx.com/en/.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.